Molecule
Venlafaxine is a serotonin and norepinephrine reuptake inhibitor indicated in adults for the treatment of major Depressive Disorder (MDD), among other approved uses. It is available as extended-release capsules, tablets and extended-release tablets for oral use. MedsAcross supplies Venlafaxine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Effexor XR is indicated in adults for the treatment of: • Major Depressive Disorder (MDD) • Generalized Anxiety Disorder (GAD) • Social Anxiety Disorder (SAD) • Panic Disorder (PD) Effexor XR is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of adults with: • Major Depressive Disorder (MDD). • Generalized Anxiety Disorder (GAD). • Social Anxiety Disorder (SAD). • Panic Disorder (PD)
Source: US FDA prescribing information
The mechanism of action of venlafaxine in the treatment of MDD, GAD, SAD, and PD is unclear, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake.
Source: US FDA prescribing information
Indication Starting Dose Target Dose Maximum Dose MDD 37.5-75 mg/day 75 mg/day 225 mg/day GAD 37.5-75 mg/day 75 mg/day 225 mg/day SAD 75 mg/day 75 mg/day 75 mg/day PD 37.5 mg/day 75 mg/day 225 mg/day • Take once daily with food. Capsules should be taken whole, do not divide, crush, chew, or dissolve. • When discontinuing treatment, reduce the dose gradually. • Renal impairment: reduce the total daily dose by 25% to 50% in patients with renal impairment. Reduce the total daily dose by 50% or more in patients undergoing dialysis or with severe renal impairment. • Hepatic impairment: reduce the daily dose by 50% in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment or hepatic cirrhosis, it may be necessary to reduce the dose by more than 50%.
Source: US FDA prescribing information
Effexor XR is contraindicated in patients: • with known hypersensitivity to venlafaxine hydrochloride, desvenlafaxine succinate or to any excipients in the formulation. • taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of the risk of serotonin syndrome. • Hypersensitivity to venlafaxine hydrochloride, desvenlafaxine succinate, or any excipients in the Effexor XR formulation. • Concomitant use of monoaminoxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI.
Source: US FDA prescribing information
Boxed warning (suicidal thoughts and behaviors): Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and emergence of suicidal thoughts and behaviors. Effexor XR is not approved for use in pediatric patients. • Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. If it occurs, discontinue Effexor XR and serotonergic agents and initiate supportive treatment. • Elevated Blood Pressure: Control hypertension before initiating treatment. Monitor blood pressure regularly during treatment. • Increased Risk of Bleeding: Concomitant use of aspirin, NSAIDs, other antiplatelet drugs, warfarin, and other anticoagulants may increase risk.
Source: US FDA prescribing information
The following adverse reactions are discussed in more detail in other sections of the labeling: • Hypersensitivity • Suicidal Thoughts and Behaviors in Adolescents and Young Adults • Serotonin Syndrome • Elevated Blood Pressure • Increased Risk of Bleeding • Angle-Closure Glaucoma • Activation of Mania/Hypomania • Discontinuation Syndrome • Seizure • Hyponatremia • Weight and Height Changes in Pediatric Patients • Appetite Changes in Pediatric Patients • Interstitial Lung Disease and Eosinophilic Pneumonia • Sexual Dysfunction Most common adverse reactions (incidence ≥5% and at least twice the rate of placebo): nausea, somnolence, dry mouth, sweating, abnormal ejaculation, anorexia, constipation, impotence (men), and libido decreased.
Source: US FDA prescribing information
Drugs Having Clinically Important Interactions with Effexor XR Table 15: Clinically Important Drug Interactions with Effexor XR Monoamine Oxidase Inhibitors (MAOI) Clinical Impact The concomitant use of SNRIs, including Effexor XR, with MAOIs increases the risk of serotonin syndrome. Intervention Concomitant use of Effexor XR is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue. Other Serotonergic Drugs Clinical Impact Concomitant use of Effexor XR with other serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. John's Wort) increases the risk of serotonin syndrome. Intervention Monitor for symptoms of serotonin syndrome when Effexor XR is used concomitantly with other drugs that may affect the serotonergic neurotransmitter systems.
Source: US FDA prescribing information
Store at controlled room temperature, 20° to 25°C (68° to 77°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
19 presentations of Venlafaxine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Venlafaxine 75 mg extended-release capsuleOralGeneric name | — | US FDA | Available on request |
| Venlafaxine 37.5 mg extended-release capsuleOralGeneric name | — | US FDA | Available on request |
| Venlafaxine 150 mg extended-release capsuleOralGeneric name | — | US FDA | Available on request |
| Venlafaxine 75 mg tabletOralGeneric name | — | US FDA | Available on request |
| Venlafaxine 37.5 mg tabletOralGeneric name | — | US FDA | Available on request |
| Venlafaxine 100 mg tabletOralGeneric name | — | US FDA | Available on request |
| Venlafaxine 25 mg tabletOralGeneric name | — | US FDA | Available on request |
| Venlafaxine 50 mg tabletOralGeneric name | — | US FDA | Available on request |
| Venlafaxine 150 mg extended-release tabletOralGeneric name | — | US FDA | Available on request |
| Venlafaxine 75 mg extended-release tabletOralGeneric name | — | US FDA | Available on request |
| Venlafaxine 225 mg extended-release tabletOralGeneric name | — | US FDA | Available on request |
| Venlafaxine 37.5 mg extended-release tabletOralGeneric name | — | US FDA | Available on request |
| Venlafaxine 225 mg tabletOralGeneric name | — | US FDA | Available on request |
| Venlafaxine 150 mg tabletOralGeneric name | — | US FDA | Available on request |
| Effexor XR 150 mg extended-release capsuleOral | Viatris Specialty | US FDA | Available on request |
| Effexor XR 37.5 mg extended-release capsuleOral | Viatris Specialty | US FDA | Available on request |
| Effexor XR 75 mg extended-release capsuleOral | Viatris Specialty | US FDA | Available on request |
| Venlafaxine 100 mg extended-release capsuleOralGeneric name | — | US FDA | Available on request |
| Venlafaxine 112.5 mg extended-release tabletOralGeneric name | — | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 28 December 1993 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Venlafaxine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 19 presentations of Venlafaxine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Venlafaxine, including Effexor XR.
Yes. The US FDA first approved Venlafaxine on 28 December 1993, according to Drugs@FDA.
No listed presentation of Venlafaxine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Venlafaxine is classified under ATC code N06AX16 (Venlafaxine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.